Atlas market file · Equity · United States
TELA Bio, Inc.TELA
- Last close
- 0.86
- Change
- -6.01%
- 96-bar range
- 0.501 – 1.27
- As of
- 6 Aug 2026
TELA Bio, Inc. is a surgical & medical instruments & apparatus issuer listed as TELA on NASDAQ. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
- Identity
- Nasdaq Trader
- Chart rail
- TradingView
- File state
- Public profile
TELA
Equity · evidence first
Static Daily candlestick snapshot from the approved cache, drawn on a labelled price axis: green bodies closed up, red closed down, wicks span each bar's high-to-low range. The live TradingView link stays available; the public profile never embeds a widget that can render the wrong symbol.
▮ up candle ▮ down candle
Weekly outlook: the last 104 weekly closes (-70.95% over the window).
Source rail: Yahoo Finance chart API (TELA). This dated snapshot is the crawlable Atlas reference.
Live market viewTradingView · provider feed Open view ->
Open the attributed TradingView market view for TELA. The dated Atlas snapshot above remains the crawlable reference; exchange data in this panel may be live or delayed as labelled by TradingView.
TELA public profile
Surgical & medical instruments & apparatus issuer. TELA Bio, Inc. is connected to current market context, cited company sources and its retained research file.
TELA Bio, Inc. trades as TELA on NASDAQ. TELA Bio, Inc. (TELA) has a latest verified close of 0.86, down 6.01%, dated 6 Aug 2026.
Open the chart, inspect attributed company evidence and continue into the fuller research file without losing this market context. Atlas files TELA under USA Stocks for browsing.
What changed for TELA Bio, Inc. today
TELA Bio, Inc. reported Q1 2026 revenue of $19.1M, a 3% increase year-over-year, with European sales surging to 41% of total revenue. Despite this growth, the company posted a net loss of $12.3M and negative operating cash flow of $11.2M, raising concerns about its ability to convert top-line gains into profitability.
The biotech firm’s official website touts its product portfolio, including images of medical devices, but SEC filings reveal a company straining under $75.1M in liabilities against just $69.9M in assets. Inventory levels rose $2.2M during the quarter, even as cash reserves dipped to $39.5M, suggesting aggressive stockpiling amid uncertain demand.
Insider trading activity has spiked recently, with multiple Form 4 filings in July and June showing executives buying and selling shares. The company’s diluted EPS of -$0.21 and negative stockholders’ equity of $-5.2M contrast sharply with its guidance for full-year 2026 revenue growth of at least 8% over 2025.
TELA’s stock remains a speculative play, with risks tied to its cash burn rate, high leverage, and reliance on European markets. Catalysts include potential regulatory approvals, sustained European growth, and the outcome of its ongoing R&D programs.
Sources & evidence · 10 links
This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.
TELA technical readout
Directional bias up. Wilder ADX and ATR computed from Atlas approved daily OHLC through 2026-07-28. Indicators are descriptive statistics, not investment advice.
Open an Atlas research path on TELA
FreedomCore Atlas can expand this public profile into source-led research files with company snapshots, valuation context, filings and segment detail, source packs, and equity briefs. Each path keeps the underlying public sources visible.
Open Atlas workstation ->Keep TELA research in your Atlas archive
Free Atlas includes the public profile and one owned welcome research artifact after account setup. Atlas Pro adds up to 25 custom research runs a day, a 500-symbol watchlist, saved report versions, and eligible PDF, CSV, and email artifacts. Evidence holds still apply and never become an unverified download. £12/month founding price, locked for life. Research only; not investment advice.
Checking Atlas access...
TELA FAQ
What is TELA Bio, Inc. (TELA)?TELA Bio, Inc. (TELA) has a latest verified close of 0.86, down 6.01%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates,...
TELA Bio, Inc. (TELA) has a latest verified close of 0.86, down 6.01%, dated 6 Aug 2026. Use this page to check the price chart, company context, source-backed updates, risks and evidence before opening the full Atlas research file.
What does Atlas show for TELA?TELA Bio, Inc. (TELA) has a latest verified close of 0.86, down 6.01%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and...
TELA Bio, Inc. (TELA) has a latest verified close of 0.86, down 6.01%, dated 6 Aug 2026. It brings the latest available chart, company context, cited sources, risks and the route into the full Atlas research file together. Atlas files TELA under USA Stocks for browsing.
How often is the TELA page updated?The TELA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the...
The TELA public file is refreshed when a newer verified market bar, company filing, official release or material source update is available. The visible date shows the freshness of the current market snapshot.
Which sources does Atlas use for TELA?The TELA file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:TELA. SEC EDGAR provides the filing anchor for this issuer. The page separates...
The TELA file starts with SEC EDGAR filings, Nasdaq Trader and TradingView NASDAQ:TELA. SEC EDGAR provides the filing anchor for this issuer. The page separates verified market context from company evidence and shows open evidence gaps instead of filling them with assumptions.
Can Atlas run a full research brief on TELA?Yes. The workstation can open TELA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Yes. The workstation can open TELA, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.
Is this TELA page investment advice?No. The TELA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise...
No. The TELA page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a trading instruction, or a promise of returns.
Methodology
This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link when verified bars are available; otherwise the page keeps the verified TradingView route as an explicit fallback.
Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.
Profile last updated: 2026-08-07. Browse FreedomCore Atlas research notes →